197 related articles for article (PubMed ID: 37756382)
1. Mesoporous Matrices as a Promising New Generation of Carriers for Multipolymorphic Active Pharmaceutical Ingredient Aripiprazole.
Minecka A; Tarnacka M; Jurkiewicz K; Żakowiecki D; Kamiński K; Kamińska E
Mol Pharm; 2023 Nov; 20(11):5655-5667. PubMed ID: 37756382
[TBL] [Abstract][Full Text] [Related]
2. Molecular-level insight into hot-melt loading and drug release from mesoporous silica carriers.
Lizoňová D; Mužík J; Šoltys M; Beránek J; Kazarian SG; Štěpánek F
Eur J Pharm Biopharm; 2018 Sep; 130():327-335. PubMed ID: 30012403
[TBL] [Abstract][Full Text] [Related]
3. Electrosprayed mesoporous particles for improved aqueous solubility of a poorly water soluble anticancer agent: in vitro and ex vivo evaluation.
Sayed E; Karavasili C; Ruparelia K; Haj-Ahmad R; Charalambopoulou G; Steriotis T; Giasafaki D; Cox P; Singh N; Giassafaki LN; Mpenekou A; Markopoulou CK; Vizirianakis IS; Chang MW; Fatouros DG; Ahmad Z
J Control Release; 2018 May; 278():142-155. PubMed ID: 29605567
[TBL] [Abstract][Full Text] [Related]
4. Tuning the Physical State of Aripiprazole by Mesoporous Silica.
Kramarczyk D; Knapik-Kowalczuk J; Klimontko J; Kurek M; Jachowicz R; Paluch M
Mol Pharm; 2024 May; 21(5):2315-2326. PubMed ID: 38644570
[TBL] [Abstract][Full Text] [Related]
5. Nanoconfinement of a Pharmaceutical Cocrystal with Praziquantel in Mesoporous Silica: The Influence of the Solid Form on Dissolution Enhancement.
Salas-Zúñiga R; Mondragón-Vásquez K; Alcalá-Alcalá S; Lima E; Höpfl H; Herrera-Ruiz D; Morales-Rojas H
Mol Pharm; 2022 Feb; 19(2):414-431. PubMed ID: 34967632
[TBL] [Abstract][Full Text] [Related]
6. Effect of solvent selection on drug loading and amorphisation in mesoporous silica particles.
Šoltys M; Kovačík P; Dammer O; Beránek J; Štěpánek F
Int J Pharm; 2019 Jan; 555():19-27. PubMed ID: 30395956
[TBL] [Abstract][Full Text] [Related]
7. Hierarchical Macro-Mesoporous Silica Monolithic Tablets as a Novel Dose-Structure-Dependent Delivery System for the Release of Confined Dexketoprofen.
Kozakiewicz-Latała M; Marciniak D; Krajewska K; Złocińska A; Prusik K; Karolewicz B; Nartowski KP; Pudło W
Mol Pharm; 2023 Jan; 20(1):641-649. PubMed ID: 36533661
[TBL] [Abstract][Full Text] [Related]
8. Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug-Polymer Immiscibility to Enable Processing for Solid Dosage Forms.
Stocker MW; Healy AM; Ferguson S
Mol Pharm; 2020 Sep; 17(9):3412-3424. PubMed ID: 32852215
[TBL] [Abstract][Full Text] [Related]
9. Drug loading to mesoporous silica carriers by solvent evaporation: A comparative study of amorphization capacity and release kinetics.
Šoltys M; Zůza D; Boleslavská T; Machač Akhlasová S; Balouch M; Kovačík P; Beránek J; Škalko-Basnet N; Flaten GE; Štěpánek F
Int J Pharm; 2021 Sep; 607():120982. PubMed ID: 34371148
[TBL] [Abstract][Full Text] [Related]
10. How Molecular Mobility, Physical State, and Drug Distribution Influence the Naproxen Release Profile from Different Mesoporous Silica Matrices.
d'Orey P; Cordeiro T; Lourenço MAO; Matos I; Danède F; Sotomayor JC; Fonseca IM; Ferreira P; Correia NT; Dionísio M
Mol Pharm; 2021 Mar; 18(3):898-914. PubMed ID: 33461296
[TBL] [Abstract][Full Text] [Related]
11. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs.
Maleki A; Kettiger H; Schoubben A; Rosenholm JM; Ambrogi V; Hamidi M
J Control Release; 2017 Sep; 262():329-347. PubMed ID: 28778479
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous Drug Delivery System: From Physical Properties of Drug in Solid State to Controlled Release.
Wang Y; Li F; Xin J; Xu J; Yu G; Shi Q
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110638
[TBL] [Abstract][Full Text] [Related]
13. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
[TBL] [Abstract][Full Text] [Related]
14. Application of commercially available mesoporous silica for drug dissolution enhancement in oral drug delivery.
Baumgartner A; Planinšek O
Eur J Pharm Sci; 2021 Dec; 167():106015. PubMed ID: 34547382
[TBL] [Abstract][Full Text] [Related]
15. High loading of lipophilic compounds in mesoporous silica for improved solubility and dissolution performance.
Benedikt Brenner M; Wüst M; Kuentz M; Wagner KG
Int J Pharm; 2024 Apr; 654():123946. PubMed ID: 38417728
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery.
Heikkilä T; Salonen J; Tuura J; Kumar N; Salmi T; Murzin DY; Hamdy MS; Mul G; Laitinen L; Kaukonen AM; Hirvonen J; Lehto VP
Drug Deliv; 2007 Aug; 14(6):337-47. PubMed ID: 17701523
[TBL] [Abstract][Full Text] [Related]
17. Probing the Amorphous State of Pharmaceutical Compounds Within Mesoporous Material Using Pair Distribution Function Analysis.
Garcia-Bennett AE; Lau M; Bedford N
J Pharm Sci; 2018 Aug; 107(8):2216-2224. PubMed ID: 29649468
[TBL] [Abstract][Full Text] [Related]
18. A Mechanistic Model for Predicting the Physical Stability of Amorphous Solid Dispersions.
Ojo AT; Lee PI
J Pharm Sci; 2021 Apr; 110(4):1495-1512. PubMed ID: 32818440
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of dicarboxylic acids salt of aripiprazole with enhanced physicochemical properties.
Hamideh A; Rahman Z; Dharani S; Khuroo T; Mohamed EM; Nutan MTH; Reddy IK; Khan MA
Pharm Dev Technol; 2021 Apr; 26(4):455-463. PubMed ID: 33653226
[TBL] [Abstract][Full Text] [Related]
20. Polymorphism and crystallization of active pharmaceutical ingredients (APIs).
Lu J; Rohani S
Curr Med Chem; 2009; 16(7):884-905. PubMed ID: 19275600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
